NASTECH PHARM CO, (NSTK) Stock Research Free Stock Rating

Company Profile

Nastech Pharmaceutical Company, Inc., a pharmaceutical company, engages in the development and commercialization of intranasal drug delivery technologies and products for small and large molecule drugs. The company's proprietary technologies focus on the delivery of small and large molecule drugs by nasal administration. Nastech develops a diverse product portfolio across various therapeutic areas, including products targeted for the treatment of obesity, sexual dysfunction, pain management, and osteoporosis. The company has collaboration agreements with Merck & Co., Inc. for the development of Peptide YY, an obesity product candidate, which is in Phase I clinical trial. In addition, it develops products for osteoporosis; and in collaboration with Par Pharmaceutical, Inc., it develops Parathyroid Hormone (PTH), which is in Phase I clinical trials and calcitonin-salmon intranasal spray. The company was founded in 1983 and is headquartered in Bothell, Washington.

Latest Headlines

MDRNA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (EDGAR Online)

MDRNA, INC. Financials (EDGAR Online Financials)

TheStreet.com Rates 37 New ETFs (at TheStreet.com)

NASTECH PHARMACEUTICAL CO INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (EDGAR Online)

NASTECH PHARMACEUTICAL CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement (EDGAR Online)

NASTECH PHARMACEUTICAL CO INC Financials (EDGAR Online Financials)

NASTECH PHARMACEUTICAL CO INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo (EDGAR Online)

NASTECH PHARMACEUTICAL CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or (EDGAR Online)

NASTECH PHARMACEUTICAL CO INC Files SEC form 8-K, Other Events (EDGAR Online)

NASTECH PHARMACEUTICAL CO INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities (EDGAR Online)